Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi Pushes For Fast-Track Approval Of Flu Treatment Peramivir

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Shionogi announced Sept. 30 it is preparing to submit an application for approval for influenza treatment peramivir for A/H1N1 and other varieties of flu

You may also be interested in...



Shionogi Files Early NDA For Flu Drug Peramivir, Aims For 3 Million User Annual Supply

Shionogi announced Nov. 4 the company filed a new drug application for influenza drug peramivir with Japan's Ministry of Health, Labor and Welfare in October. The early NDA submission came just three month after the Osaka-based company completed a Phase III study for the drug

Shionogi Files Early NDA For Flu Drug Peramivir, Aims For 3 Million User Annual Supply

Shionogi announced Nov. 4 the company filed a new drug application for influenza drug peramivir with Japan's Ministry of Health, Labor and Welfare in October. The early NDA submission came just three month after the Osaka-based company completed a Phase III study for the drug

Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota, Japanese Daiichi Sankyo

PERTH, Australia - Australian biotech Biota Holdings announced positive Phase III results of its Asian clinical trials for second-generation influenza treatment CS-8958, co-developed and co-owned with Daiichi Sankyo

Related Content

UsernamePublicRestriction

Register

SC070029

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel